Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
ID: 344574Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344574

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-022.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional), aimed at fostering innovative research that integrates engineering and physical sciences with life and biomedical sciences. This grant opportunity encourages applicants to pursue exploratory, developmental, or high-risk projects without the necessity for preliminary data, thereby promoting creative solutions to unmet biomedical research needs. The award supports a maximum of $400,000 in direct costs over three years, with applications due by January 7, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-022.html
    The Trailblazer Award for New and Early Stage Investigators, issued by the National Institutes of Health (NIH), encourages innovative research integrating engineering and physical sciences with life and biomedical sciences. This funding opportunity (PAR-24-022) allows applicants to pursue exploratory, developmental, or high-risk projects without the necessity for preliminary data, thereby fostering creative approaches to unmet biomedical research needs. The award supports a maximum of $400,000 in direct costs over three years. Eligible applicants include NIH-defined New and Early Stage Investigators. Key points include the emphasis on projects that contribute to innovation, as well as the encouragement of applications from underrepresented groups in research. The funding application process requires strict adherence to guidelines, with critical review criteria focusing on significance, investigator capabilities, innovation, and the overall approach. A distinctive aspect of this opportunity is the encouragement of high-risk projects that may lack extensive preliminary data, promoting novel and non-incremental ideas. Notably, proposals involving clinical trials are limited to early-stage studies (Phase I or feasibility) aligned with technology development goals. The aim is to catalyze transdisciplinary research that significantly advances biomedical knowledge and practices.
    Similar Opportunities
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Grants for New Investigators to Promote Diversity in Health-Related Research" (R21 Clinical Trial Optional) to support new investigators from diverse backgrounds in conducting small research projects. This funding opportunity aims to facilitate the transition to independent research careers for individuals who have not previously secured over $125,000 in direct costs of research funding, specifically targeting those from historically underrepresented groups in biomedical research. The grants, which can last up to three years with a maximum direct cost of $125,000 annually, are intended to foster innovation and address health disparities in underserved populations. Interested applicants must submit their proposals by January 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 mechanism, aimed at fostering innovative engineering solutions to advance biomedical research. This funding opportunity encourages applications from a diverse range of organizations, including higher education institutions and nonprofits, to support exploratory projects that demonstrate feasibility and potential utility in addressing critical challenges in biomedical research and clinical care delivery, without involving clinical trials. The initiative emphasizes collaboration between quantitative and physical scientists and biomedical researchers, aiming to facilitate early-stage developments that can lead to significant advancements in medical technologies and methods. The funding ceiling is set at $275,000 over two years, with applications due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.